Piramal Pharma Limited Announces Results for Q1 FY27

Particulars

Q1FY27

Q1FY26

% Change

  Revenue from Operations

2,270

1,934

17 %

      CDMO

1,187

997

19 %

      CHG

743

637

17 %

      PCH

347

302

15 %

  EBITDA

285

165

72 %

  EBITDA Margin

12.5 %

8.5 %

  PAT (before exceptional item)

(69)

(102)

32 %

  Exceptional Item

-

21

NM

  PAT (after exceptional item)

(69)

(82)

15 %

Key Business Highlights

Contract Development and Manufacturing Organization (CDMO):

• Broad-based growth across India and overseas sites, supported by healthy order inflows and strong execution across the network.
• Strengthened commercial capabilities through an expanded commercial team, sharper market coverage and deeper customer engagement.
• Improved Biopharma funding supported increase in RFPs, though customer decision-making timelines remains prolonged. Maintaining our win rates and conversion of these RFPs into orders will be the key driver of growth.
• Improved Execution and Operating Leverage: Higher utilization, pricing discipline and operational excellence drove EBITDA margin expansion across most sites despite inflationary pressures.
• Building upon our ADC Capabilities: Inaugurated the commercial-scale payload-linker suite at Riverview (US), while the Lexington (US) sterile injectable capacity expansion remains on track. 
• Strategic Partnerships: Collaborated with Ajinomoto Bio-Pharma Services for next-gen conjugation technology.
• Quality: Sellersville facility received an EIR from the US FDA. The business continues to maintain its Zero OAI track record to date.

Complex Hospital Generics (CHG):

• Inhalation Anesthesia: Retained leadership in the US Sevoflurane market with a 48% value share and witnessed encouraging traction across select ex-US markets. (Source: IQVIA)
• Kenalog®: Progressing on integration activities. Expect supplies to start from Q2FY27.
• Intrathecal Therapy: Maintained our #1 position in the US intrathecal Baclofen market. (Source: IQVIA)
• Injectable Pain Management: Collaborating with suppliers to enhance product availability. 
• Differentiated and Specialty Products: Continued investments in 505(b)(2) products, complex and differentiated generics, branded products, through in-licensing and co-development.

Piramal Consumer Healthcare (PCH):

• Power Brands: Grew 23% year-on-year and contributed 53% of Consumer Healthcare sales.
• E-commerce: Grew 40% year-on-year and contributed 28% of sales.
• i-choose: Launched a new master brand bringing together the women's intimate care portfolio under a unified identity. 
• Brand Investments: Invested approximately 12% of sales in media and trade promotion across digital and traditional channels.
• Profitable Growth: Premiumization, judicious pricing and cost-optimization initiatives helped mitigate raw-material inflation and supported EBITDA performance.

Particulars

Quarterly

Q1FY27

Q1FY26

YoY  %

Revenue from Operations

2,270

1,934

17 %

Other Income

89

58

53 %

Total Income

2,359

1,992

18 %

Material Cost

852

694

23 %

Employee Expenses

676

619

9 %

Other Expenses

547

514

6 %

EBITDA

285

165

72 %

Interest Expenses

88

86

2 %

Depreciation

224

197

13 %

Share of Net Profit of Associates

20

19

5 %

Profit Before Tax

(7)

(100)

93 %

Tax

62

3

2,211 %

Net Profit after Tax

(69)

(102)

32 %

Exceptional item1

-

21

NM

Net Profit after Tax after Exceptional Item

(69)

(82)

15 %

Event

Location & Time

Telephone Number

Conference call on 30^th July 2026

India – 09:30 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:00 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 05:00 AM

(London Time)

Toll free number

08081011573

Singapore – 12:00 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:00 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call – Click here